extended-release minoxidil tablet (VDPHL01) / Veradermics - LARVOL DELTA

Faster Onset and Superior Efficacy of an Investigational Extended-Release Oral Minoxidil Tablet (VDPHL01) Versus Topical and Immediate-Release Oral Minoxidil for Androgenetic Alopecia: Results from a Blinded Retrospective Investigator Global Assessment (AAD 2026) - "VDPHL01 produced superior frontal and vertex hair growth at 2 months versus 6 months with topical and IR oral minoxidil, suggesting VDPHL01 is faster acting and potentially superior in treating AGA. Limitations include potential differences in baseline characteristics across trials and the retrospective methodology."

Retrospective data • Alopecia • Immunology

Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting (Businesswire) - "The data to be presented include a blinded, retrospective investigator global assessment conducted by six independent dermatologists regarding the comparative perceived efficacy of VDPHL01 versus existing minoxidil formulations and the clinical potential of VDPHL01. In addition, two presentations will characterize social listening research on patient perceptions and experiences, describing general frustration with current pattern hair loss treatments."

Real-world • Retrospective data • Alopecia • Immunology

Safety and Efficacy of VDPHL01 in Males With AGA (clinicaltrials.gov) - P3 | N=480 | Active, not recruiting | Sponsor: Veradermics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Alopecia • Dermatology • Immunology

Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) (clinicaltrials.gov) - P3 | N=552 | Recruiting | Sponsor: Veradermics, Inc. | Trial completion date: Mar 2027 ➔ Jan 2028 | Trial primary completion date: Mar 2027 ➔ Jun 2027

Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

Safety and Efficacy of VDPHL01 in Males With AGA (clinicaltrials.gov) - P3 | N=480 | Recruiting | Sponsor: Veradermics, Inc. | Trial completion date: Nov 2026 ➔ Jul 2027

Trial completion date • Alopecia • Dermatology • Immunology

Safety and Efficacy of VDPHL01 in Males and Females With AGA (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: Veradermics, Inc. | Trial primary completion date: Feb 2026 ➔ Aug 2026

Trial primary completion date • Alopecia • Dermatology • Immunology

Efficacy and Safety of VDPHL01 in Males With AGA (clinicaltrials.gov) - P2/3 | N=480 | Active, not recruiting | Sponsor: Veradermics, Inc. | Trial primary completion date: Jul 2026 ➔ Feb 2026

Trial primary completion date • Alopecia • Dermatology • Immunology

Comparative Efficacy of an Investigational Oral Minoxidil Extended-Release Tablet Versus Existing Minoxidil Formulations in Androgenetic Alopecia: A Blinded Retrospective IGA Analysis (EADV 2025) - "Introduction The use of minoxidil for the treatment of androgenetic alopecia (AGA), both as a topical and as an immediate release (IR) oral tablet, has increased in recent years; however, there are still no oral formulations of minoxidil that are FDA approved for AGA. Pending further clinical development, these findings suggest VDPHL01 is a potential best-in-class treatment for AGA. Study limitations include potential differences in baseline characteristics of subjects across trials and inherent limitations in retrospective photography-based review methodologies."

Late-breaking abstract • Retrospective data • Alopecia • Immunology

Safety and Efficacy of VDPHL01 in Males and Females With AGA (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: Veradermics, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2026 ➔ Aug 2026

Enrollment closed • Trial completion date • Alopecia • Dermatology • Immunology

Efficacy and Safety of VDPHL01 in Males With AGA (clinicaltrials.gov) - P2/3 | N=480 | Active, not recruiting | Sponsor: Veradermics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Alopecia • Dermatology • Immunology

Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) (clinicaltrials.gov) - P3 | N=552 | Recruiting | Sponsor: Veradermics, Inc.

New P3 trial • Alopecia • Dermatology • Immunology

Safety and Efficacy of VDPHL01 in Males With AGA (clinicaltrials.gov) - P3 | N=480 | Recruiting | Sponsor: Veradermics, Inc.

New P3 trial • Alopecia • Dermatology • Immunology

Safety and Efficacy of VDPHL01 in Males and Females with AGA (clinicaltrials.gov) - P2 | N=70 | Recruiting | Sponsor: Veradermics, Inc. | N=20 ➔ 70 | Trial completion date: Aug 2025 ➔ Mar 2026 | Trial primary completion date: Aug 2025 ➔ Feb 2026

Enrollment change • Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

Efficacy and Safety of VDPHL01 in Males with AGA (clinicaltrials.gov) - P2/3 | N=480 | Recruiting | Sponsor: Veradermics, Inc.

New P2/3 trial • Alopecia • Dermatology • Immunology

Safety and Efficacy of VDPHL01 in Males With AGA (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Veradermics, Inc.

New P2 trial • Alopecia • Dermatology • Immunology